A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis.
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The t(8;21)(q22;q22) translocation is one of the most common genetic abnormalities in acute myeloid leukemia (AML), identified in 15% of all cases of AML, including 40-50% of FAB M2 subtype and rare cases of M0, M1 and M4 subtypes. The most commonly known AML1-ETO fusion protein (full-length AML1-ETO) from this translocation has 752 amino acids and contains the N-terminal portion of RUNX1 (also known as AML1, CBFalpha2 or PEBP2alphaB), including its DNA binding domain, and almost the entire RUNX1T1 (also known as MTG8 or ETO) protein. Although alterations of gene expression and hematopoietic cell proliferation have been reported in the presence of AML1-ETO, its expression does not lead to the development of leukemia. Here, we report the identification of a previously unknown alternatively spliced isoform of the AML1-ETO transcript, AML1-ETO9a, that includes an extra exon, exon 9a, of the ETO gene. AML1-ETO9a encodes a C-terminally truncated AML1-ETO protein of 575 amino acids. Expression of AML1-ETO9a leads to rapid development of leukemia in a mouse retroviral transduction-transplantation model. More importantly, coexpression of AML1-ETO and AML1-ETO9a results in the substantially earlier onset of AML and blocks myeloid cell differentiation at a more immature stage. These results indicate that fusion proteins from alternatively spliced isoforms of a chromosomal translocation may work together to induce cancer development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the ETO domains that recruit corepressors are frequently deleted from the RUNX1-ETO leukemia fusion protein seen in primary AML cells.41,42”
From RUNX1 regulates corepressor interactions of PU.1 (2011) · cites this paper as [42]
Citations
Cites
The Transcriptional Landscape of the Mammalian Genome
Carninci, P., Kasukawa, T., Katayama, S., Gough, J., Frith, M. C., Maeda, N., Oyama, R., Ravasi, T., Lenhard, B., Wells, C., et al. (2005) · Science · doi:10.1126/science.1112014 · Cited by 3,499 · cited 1×
“The widespread existence of alternatively spliced forms of transcripts has only recently been recognized as a result of advances in mammalian genomic analysi”
BackgroundA clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 1×
“We performed hematopoietic progenitor population analysis in leukemic mice with multicolor staining as described previousl”
MethodIdentification of Clonogenic Common Lymphoid Progenitors in Mouse Bone Marrow
Kondo, M., Weissman, I. L., & Akashi, K. (1997) · Cell · doi:10.1016/s0092-8674(00)80453-5 · Cited by 2,253 · cited 1×
“We performed hematopoietic progenitor population analysis in leukemic mice with multicolor staining as described previousl”
MethodPear, W. S., Miller, J. P., Xu, L., Pui, J. C., Soffer, B., Quackenbush, R. C., Pendergast, A. M., Bronson, R., Aster, J. C., Scott, M. L., et al. (1998) · Blood · doi:10.1182/blood.v92.10.3780 · Cited by 755
Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., & Ohki, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05933.x · Cited by 498
Higuchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J., & Downing, J. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00016-8 · Cited by 440 · cited 1×
“It is well known that the commonly studied full-length AE protein is not sufficient to induce leukemia in either human or mouse hematopoietic cell”
BackgroundYuan, Y., Zhou, L., Miyamoto, T., Iwasaki, H., Harakawa, N., Hetherington, C. J., Burel, S. A., Lagasse, E., Weissman, I. L., Akashi, K., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171321298 · Cited by 431 · cited 1×
“Full-length AML1-ETO is specifically expressed in myeloid cells under the control of the MRP8 promoter in MRP8-AE transgenic mic”
BackgroundSelf-citationBethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice
Kogan, S. C., Ward, J. M., Anver, M. R., Berman, J. J., Brayton, C., Cardiff, R. D., Carter, J. S., de Coronado, S., Downing, J. R., Fredrickson, T. N., et al. (2002) · Blood · doi:10.1182/blood.v100.1.238 · Cited by 418 · cited 1×
“According to the classification of the hematopathology subcommittee of the Mouse Model of Human Cancers Consortium (MMHCC”
MethodOkuda, T., Cai, Z., Yang, S., Lenny, N., Lyu, C.-J., van Deursen, J. M. A., Harada, H., & Downing, J. R. (1998) · Blood · doi:10.1182/blood.v91.9.3134 · Cited by 372
The t(8;21) Fusion Protein Interferes with AML-1B-Dependent Transcriptional Activation
Meyers, S., Lenny, N., & Hiebert, S. W. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1974 · Cited by 368
Cited by
Items 201–280 of 280
Decoding of exon splicing patterns in the human RUNX1–RUNX1T1 fusion gene
Grinev, V. V., Migas, A. A., Kirsanava, A. D., Mishkova, V., Siomava, N., Ramanouskaya, T. V., Vaitsiankova, A., Ilyushonak, I. M., Nazarov, P. V., Vallar, L., et al. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.08.017 · Cited by 18
SERPINB13 is a novel RUNX1 target gene
Boyapati, A., Ren, B., & Zhang, D. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.06.107 · Cited by 9
“Reduction of endogenous RUNX1 was detected by immunoblotting with a RUNX1 specific antibody [23].”
BackgroundSelf-citationKDM4B promotes acute myeloid leukemia associated with AML1‐ETO by regulating chromatin accessibility
Ueda, T., Kanai, A., Komuro, A., Amano, H., Ota, K., Honda, M., Kawazu, M., & Okada, H. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00030 · Cited by 8
Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO
Hines, R., Boyapati, A., & Zhang, D. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.05.005 · Cited by 10
“For example, in mouse models, until recently AML1-ETO had been unable to promote leukemia by itself; however, when the Nervy homology regions 3 and 4 (NHR3 and NHR4) at the C-terminus of AML1-ETO were removed, AML1-ETO became strongly leukemogenic on its own [24;25].”
BackgroundSelf-citationPharmacodynamic markers for histone deacetylase inhibitor development
Heinzel, T., & Krämer, O. H. (2007) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2008.06.003 · Cited by 13
Ponnusamy, K., Chen-Wichmann, L., Kuvardina, O. N., Lausen, J., Henschler, R., & Wichmann, C. (2014) · Haematologica · doi:10.3324/haematol.2014.106088 · Cited by 9
Inhibiting AGTR1 reduces AML burden and protects the heart from cardiotoxicity in mouse models
Pan, Y., Wang, C., Zhou, W., Shi, Y., Meng, X., Muhammad, Y., Hammer, R., Jia, B., Zheng, H., Li, D., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl5931 · Cited by 10
STING is crucial for the survival of RUNX1::RUNX1T1 leukemia cells
Sun, Y., Wu, Y., Pang, G.-Z., Huang, J., Sheng, M., Xie, J., Chen, P., Wang, Y., Yin, D., Zhao, G., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02383-8 · Cited by 9
Self-citationBartel, Y., Grez, M., & Wichmann, C. W. (2013) · BioMed Research International · doi:10.1155/2013/297692 · Cited by 16
“Furthermore, recent studies have shown that an alternatively spliced isoform of RUNX1/ETO lacking the C-terminal NCoR binding domain coexists with full length RUNX1/ETO in patients and strongly induces leukemia development in mice [42].”
BackgroundStem Cell Modeling of Core Binding Factor Acute Myeloid Leukemia
Mosna, F., & Gottardi, M. (2016) · Stem Cells International · doi:10.1155/2016/7625827 · Cited by 11
“On the opposite, an alternatively spliced isoform of the RUNX1-RUNX1T1/AML1-ETO transcript, AML1-ETO9a, which includes an extra exon (9a) of the ETO gene, leads to the rapid development of acute leukemia in a mouse retroviral transduction-transplantation model [42].”
Genetic Markers in Sporadic Tumors
Tamborini, E., Perrone, F., Frattini, M., Negri, T., Aiello, A., Gloghini, A., Carbone, A., Pilotti, S., & Pierotti, M. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-470-4_3 · Cited by 8
“Additional genetic hits are necessary to induce overt neoplastic transformation, some of which being identified as FLT3LM [186], cKIT mutation/overexpression [187–188], WT1 overexpression [189], and an alternatively spliced isoform of t(8;21) transcript [190].”
BackgroundRNA binding protein‐directed control of leukemic stem cell evolution and function
Joshi, P., Chahi, A. K., Liu, L., Moreira, S., Vujovic, A., & Hope, K. J. (2024) · HemaSphere · doi:10.1002/hem3.116 · Cited by 10
“144,145 Overall, these studies demonstrate that genetic ‐ and molecular ‐ level dysregulation of splicing is a pro ‐ leukemic pathogenic feature that is also shared in LSCs and likely carried forward from pre ‐ LSCs.”
BackgroundYan, M., Liu, M., Davis, A. G., Stoner, S. A., & Zhang, D. (2023) · Leukemia · doi:10.1038/s41375-023-02063-z · Cited by 7
Self-citationA comprehensive landscape of transcription profiles and data resources for human leukemia
Luo, M., Miao, Y., Ke, Y., Guo, A., & Zhang, Q. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008410 · Cited by 9
Self-citationAgrawal, M., Schwarz, P., Giaimo, B. D., Bedzhov, I., Corbacioglu, A., Weber, D., Gaidzik, V. I., Jahn, N., Rücker, F. G., Schroeder, T. A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0551-4 · Cited by 7
Ahmed, H., Patnana, P. K., Al-Matary, Y. S., Fiori, M., Vorwerk, J., Ahmad, M. H., Dazert, E., Oelschläger, L., Künstner, A., Opalka, B., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178301 · Cited by 7
“Wild-type C57BL/6J mice were used to establish the MLL-AF9-induced leukemic model, as described previously [33,34].”
Yu, C., Sheng, Y., Yu, F., Ni, H., Qiu, A., Huang, Y., & Qian, Z. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163911 · Cited by 7
The Etiology of Acute Leukemia
Nichol, J. N., Assouline, S. E., & Miller, W. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3764-2_14 · Cited by 7
Fukunaga, J.-I., Nomura, Y., Tanaka, Y., Torigoe, H., Nakamura, Y., Sakamoto, T., & Kozu, T. (2020) · FEBS Letters · doi:10.1002/1873-3468.13914 · Cited by 6
A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1
Solari, L., Bauer, T., Dicker, F., Haferlach, C., Grießhammer, M., Schnittger, S., Becker, H., & Lübbert, M. (2013) · Leukemia · doi:10.1038/leu.2013.53 · Cited by 5
Supplementary Material and Methods
Rosato, P. C., Anastasiadou, E., Garg, N., Lenze, D., Boccellato, F., Vincenti, S., Severa, M., Coccia, E. M., Bigi, R., Cirone, M., et al. (2012) · Cited by 3
Ji, Y., Huang, Y., Thomas, T., Kapti, E. G., Tachibana, R., Lark, J., Berezniuk, I., Guo, L., Ali, M. A., Mims, K., et al. (2025) · Blood · doi:10.1182/blood.2024026271 · Cited by 6
Desai, R. H., Taghavi, S., Chase, J. C., Chopra, M., Chien, J., Browett, P., Kakadia, P. M., & Bohlander, S. K. (2019) · Leukemia · doi:10.1038/s41375-019-0657-8 · Cited by 4
Modelling t(8;21) acute myeloid leukaemia ‐ What have we learned?
Chin, P. S., & Bonifer, C. (2020) · MedComm · doi:10.1002/mco2.30 · Cited by 4
Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Banerjee, S., Amin, S. A., & Jha, T. (2021) · Current Chemical Biology · doi:10.2174/2212796815666210203104446 · Cited by 4
Nanocolonies and diagnostics of oncological diseases associated with chromosomal translocations
Chetverina, Е. V., & Chetverin, A. B. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910130109 · Cited by 4
The Etiology of Acute Leukemia
Nichol, J. N., Kinal, M., & Miller, W. H. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_12 · Cited by 4
Deng, K., Liu, Z., Su, Y., Zhang, Z., Fan, Y., Zhang, Y., & Wang, F. (2023) · The FASEB Journal · doi:10.1096/fj.202300677r · Cited by 3
Modeling and therapeutic targeting of t(8;21) AML with/without TP53 deficiency
Zhang, W., Li, J., Yamamoto, K., & Goyama, S. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03783-3 · Cited by 3
“RUNX1-ETO9a [9], a short isoform of RUNX1-ETO, encodes a C-terminally truncated RUNX1-ETO protein with a stronger leukemogenic potential than full-length RUNX1-ETO.”
BackgroundMethodLi, Y., Cao, Z., Xing, H., Xue, Z., Liu, W., Chen, J., Mei, Y., Gu, R., Wei, H., Qiu, S., et al. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70090 · Cited by 3
“This variant has been demonstrated to exhibit potent leukemogenic activity in mouse model, and this AE9a mouse model closely mimics AML patients initiated by AML1-ETO [29].”
RUNX/CBF Transcription Factors☆
Lam, K., & Zhang, D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.98749-x · Cited by 3
Self-citationMaintenance of Leukemia-Initiating Cells Is Regulated by the CDK Inhibitor Inca1
Bäumer, N., Bäumer, S., Berkenfeld, F., Stehling, M., Köhler, G., Berdel, W. E., Müller‐Tidow, C., & Tschanter, P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115578 · Cited by 3
“Since the expression of full length AML1-ETO does not lead to the development of leukemia [19–21], we took advantage of an alternatively spliced isoform of the AML1-ETO transcript, AML1-ETO9a, which induces an acute myeloid leukemia in mice with a high penetrance [21].”
BackgroundMethodNew insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins
Li, J., Guo, C. H., Steinauer, N., & Zhang, J. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1415-1 · Cited by 4
“These mice, instead, develop ALL (Bain et al., 1997; Yan et al., 1997) and re-introducing E2A into the ALLs cause profound apoptosis (Engel and Murre, 1999).”
Molecular genetics of acute myeloid leukemia
Gruber, T. A., & Downing, J. R. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977633.009 · Cited by 3
ADAR2-repressed RNA editing: a novel mechanism contributing to t (8:21) AML leukemogenesisPreprint
Guo, M., Chan, T. H. M., An, Ö., Song, Y., Tan, Z. H., Ng, V. H. E., Cao, X., Chng, W. J., Osato, M., Yang, H. H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.18.464918 · Cited by 4
Yang, L., Lu, J., Yun, W., Yang, X., Sun, J., Ge, C., Han, F., Li, X., Min, J., He, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68509-x · Cited by 2
“Oneofthesemodels employed mouse AML cells expressing the MLL-AF9 ( MA9 ) fusion oncogene as donor cells, which recapitulates the monocytic (M5-AML) subtype;andtheothermodelused AML-ETO9a ( AE9a )-expressingAML cells,representingthegranulocytic(M2b-AML)subtype 34,35 .”
Mechanisms of Secondary Leukemia Development Caused by Treatment with DNA Topoisomerase Inhibitors
Lomov, N. A., Viushkov, V. S., & Rubtsov, M. A. (2023) · Biochemistry (Moscow) · doi:10.1134/s0006297923070040 · Cited by 2
“It was shown that leukemia development also depends on particular protein isoforms generated as a result of alternative splicing of the fusion mRNA [129, 135, 136].”
BackgroundLints, R., Walker, C. A., Delfi, O., Prouse, M., de Silva, M. P., Bohlander, S. K., & Wood, A. (2024) · Biology Open · doi:10.1242/bio.060523 · Cited by 2
“GFP (control), cDNAs encoding human RUNX1::RUNXT1 splice variant 9a (9a), human NRAS G12D oncogene fused in frame to GFP (GFPNRAS G12D ) .”
BackgroundInfluentialEpigenetic Modifications Mediated by the AML1/ETO and MLL Leukemia Fusion Proteins
Duque‐Afonso, J., Lübbert, M., & Cleary, M. L. (2013) · Springer eBooks · doi:10.1007/978-3-642-38404-2_6 · Cited by 2
Necdin modulates leukemia-initiating cell quiescence and chemotherapy response
Yao, C., Kobayashi, M., Chen, S., Nabinger, S. C., Gao, R., Liu, S. Z., Asai, T., & Liu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.20999 · Cited by 3
“In addition to MLL-AF9-induced leukemia, we also utilized a mouse model of human AML induced by the AML-ETO9a oncogene to determine the role of Necdin in leuekmia initiation and progression [16].”
MethodSu, R. J., Li, Z., Chen, P., Li, Y., Hu, C., Wang, Y., Arnovitz, S., He, M., Gurbuxani, S. K., Zuo, Z., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3667.3667 · Cited by 2
Self-citationChildhood hematopoietic stem cells constitute the permissive window for RUNX1-ETO leukemogenesis
Abdallah, M. G., Teoh, V. S. I., Dutta, B., Yokomizo, T., & Osato, M. (2023) · International Journal of Hematology · doi:10.1007/s12185-023-03605-y · Cited by 2
“However, no leukemia developed without additional cooperating mutations, unless the aggressive truncated form RUNX1ETO, namely RUNX1-ETO9a, was introduced instead of full length RUNX1-ETO [37].”
BackgroundPervasive non-triplet alternative splicing drives functional isoform diversity
Athavudeen, S., Issac, N. G., & Norris, A. D. (2026) · Nature Communications · doi:10.1038/s41467-026-71615-5 · Cited by 1
Zhang, M., Li, Y., Zhang, B., Cai, C., Li, S., He, Z., Meng, X., Wang, C., Ding, W., Wang, X., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03051-9 · Cited by 1
Splicing the way to leukemia with KIT
McArthur, G. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802192759 · Cited by 1
“Interestingly, the protein encoded by this transcript appears to increase the transforming ability of the AML1-ETO fusion protein possibility to altering the recruitment of transcriptional coregulators to the promoters of AML1 target genes [1].”
BackgroundReinforced erythroid differentiation inhibits leukemogenic potential of t(8;21) leukemia
Wang, M., Li, Y., Chen, J., Zhao, J., Zhu, J., & Yu, S. (2022) · The FASEB Journal · doi:10.1096/fj.202200026rr · Cited by 1
“In general, compared to t(15;17), t(16;16), and t(9;11) AML subtypes, t(8;21) AML has relatively higher enrichment scores in gene sets of ‘erythrocyte development,’ ‘erythrocyte maturation,’ ‘erythrocyte homeostasis,’ ‘definitive erythrocyte differentiation,’ and ‘positive regulation of erythrocyte differentiation’ (F…”
BackgroundKreissig, S., Windisch, R., & Wichmann, C. W. (2023) · Cells · doi:10.3390/cells13010078 · Cited by 3
Thanaraj, K. K., & Busanelli, L. (2024) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.542
Li, J., Sugimoto, E., Yamamoto, K., Dai, Y., Zhang, W., Chang, Y. A., Nakahara, J., Yabushita, T., Kitamura, T., Park, S., et al. (2025) · Cancer Science · doi:10.1111/cas.70170 · Cited by 1
“AML cells expressing RUNX1-ETO9a [32], a shorter isoform of RUNX1-ETO, are not monocytic but are more primitive AML cells [25].”
Gen de fusión AML1-ETO: particularidades en la leucemia mieloide aguda
Santana, H. G., Vigil, A. M. A., Alonso, C. A. D., González, Y. S., & Pacheco, M. G. (n.d.) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Analysis of Leukemogenic Gene Products in Hematopoietic Progenitor Cells
Schanda, J., Henschler, R., Grez, M., & Wichm, C. (2011) · InTech eBooks · doi:10.5772/26242 · Cited by 1
“Expression of this newly discovered splice isoform in mice also induced rapid leukemia development (Yan et al., 2006).”
BackgroundInvestigating the role of HIP1/PDGFbetaR in leukemogenesis and imatinib sensitivity.
Philips, S. T. (2010) · Deep Blue (University of Michigan)
Characterisation of the leukaemia-associated ETO homologues
Lindberg, S. R. (2006) · Lund University Publications (Lund University)
The RUNX1 Transcription Factor: A Gatekeeper in Acute Leukemia
Stocking, C., Niebuhr, B., Fischer, M., Täger, M., & Cammenga, J. (2007) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-1-4020-6469-2_14
Transcript variants of RUNX1T1: New insight into t(8;21)-positive leukemia
Kim, J., & Ahn, E.-Y. E. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.06.023
Hackanson, B. W., Becker, H., Berg, T., Binder, M., Dierks, C., Duque‐Afonso, J., Lairmore, M. D., Schäfer, H. S., Schnitzler, M., Zeiser, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6859
“However, a truncated form of AML1/ETO induces AML with high penetrance and is expressed as a splice variant of AML1/ETO (using exon 9a) in primary leukemias (12).”
BackgroundPre-clinical Modelling of Chromosomal Translocations and Inversions
Ruggero, K., & Rabbitts, T. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_20
Zhao, X., Nimer, S. D., Yates, J. R., Zhang, D., Shia, W.-J., Okumura, A. J., Yan, M., Sarkeshik, A., & Matsuura, S. (2014)
Self-citationNovel mechanisms of transcriptional regulation by leukemia fusion proteins
Gow, C. (2014) · OhioLink ETD Center (Ohio Library and Information Network)
Fejklowicz, M., & Grosicki, S. (2018) · Hematologia · doi:10.5603/hem.2018.0018
Therapeutic targeting of the leukaemic fusion genes
Issa, H. (2019)
Dependence of Acute Myeloid Leukemia Development on Membrane Protein Dipeptidyl Peptidase 4Preprint
Wang, C., Nistala, R., Cao, M., Behrens, M., Doll, D. C., Hammer, R., Nistala, P., Chang, H., Yeh, E. T. H., & Kang, X. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4052011
Dawson, M. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733181089.793545863
Hyperactive NK cells in Rag2 knockout mice inhibit the development of acute myeloid leukemiaPreprint
Sugimoto, E., Hayashi, Y., Iida, K., Asada, S., Fukushima, T., Tamura, M., Kawabata, K. C., Kawase, T., Saito, T., Yoshida, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1934697/v1
Shah, V., Giotopoulos, G., Osaki, H., Meyerhöfer, M., Meduri, E., Schubert, B., Yun, H., Horton, S. J., Singh, S. A., Haehnel, P. S., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.14.507850
Dunne, J., Gascoyne, D. M., Lister, T. A., Brady, H. J. M., Heidenreich, O. T., & Young, B. D. (2023) · doi:10.1158/0008-5472.c.6500418
Alternative Splicing and Cancer
Choksi, A., Pant, R., Nakka, K. K., Singh, M., Upreti, A., & Chattopadhyay, S. (2023) · Springer eBooks · doi:10.1007/978-981-19-8520-1_3
Mechanisms for the development of therapy-related leukaemia caused by topoisomerase inhibitors
Lomov, N. A., Viushkov, V. S., & Rubtsov, M. A. (2023) · Biochemistry (Moscow) · doi:10.31857/s0320972523070047
Leukemia and Lymphoma: An update of acute myeloid leukemia after Whole genome sequencing (WG)
Bandyopadhyay, A. K. (2024) · Magna Scientia Advanced Research and Reviews · doi:10.30574/msarr.2024.11.1.0063
“In-frame insertions in the NPM1 gene, found in ~30% of AML patients, an aberrant protein is produced that is mis localized from the nucleolus to the cytoplasm (NPMc) (41) These mutations are associated with a relatively favorable prognosis in patients that lack FLT3 ITD (38).”
BackgroundDynamic Localization of Leukemia Stem Cells via CXCL12 Regulates Leukemia ProgressionPreprint
Wang, C., Pan, Y., Dong, R., Zhou, W., Meng, X., Shi, Y., Nistala, R., Hammer, R., Li, L., & Kang, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.29.601323 · Cited by 1
t(8;21)AML patients with RUNX1e6::RUNX1T19a splice variant have poor prognosis
Fan, Y., Chen, L., Liu, S., Dang, J., Chang, J., Guo, C., Xu, Y., Guo, W., Wang, H., & Tan, Y. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06545-1
“The retroviral expression vectors MSCV-IRES-EGFP (MigR1), MigR1-HA-AE and MigR1-HA-AE9a have been previously described [12].”
WITHDRAWN: A Druggable Tumor Suppressor and Leukemic Stem Cell MarkerPreprint
Pan, Y., Meng, X., Wang, C., Zhou, W., Chen, Y., Hammer, R., Zheng, H., Hildebrandt, G. C., & Kang, X. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682831
“We then apply an explicit human-genetics safety triage: gnomAD constraint (LOEUF/pLI) 14 as a haploinsufficiency proxy; GTEx v8 15 median TPM to penalize broad or high expression in critical tissues (brain, heart, liver, kidney, lung, blood); and breadth of cis-eQTLs across tissues.”
Wilms, H. T., Ornelles, D. A., Gooding, L. R., Maganti, N., & Garnett‐Benson, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.19.695471
Liu, Q., Wang, X., Fan, J., Zheng, Y., Ye, L., Chang, W., Chen, X., Cai, Y., Lai, X., Li, Y., et al. (2026) · British Journal of Haematology · doi:10.1111/bjh.70658
“8,10,14 The AE9a/AE abundance ranged from 0% to 100% (average 45.8”
InfluentialOncogenic DHX15 mutation enhances mitochondrial metabolism and sustains leukemia stemness
Li, Q., Xing, P., Xu, J., Li, J., Chen, L., Li, X., 白银鹏, Li, G., Xie, T., Wang, L., et al. (2026) · Leukemia · doi:10.1038/s41375-026-03102-1
Self-citationLi, S., He, S., Su, Y., Wang, L., Wang, Y., Xu, Y., Li, Y., & Zhou, J. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2608310123
Self-citationCooperating Events in Core Binding Factor Leukemia Development: A Dissertation
Madera, D. (2011) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/k9gj-gr76
“The t(8;21) AML cells co-express the full-length RUNX1-ETO and the alternative spliced (and more aggressive) RUNX1-ETO9a isoform (Yan et al., 2006a).”
BackgroundInfluentialMouse Models of Myeloid Leukemia
Lorsbach, R. B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60761-384-8_37
Metadata
- Authors
- Yan, M., Kanbe, E., Peterson, L. F., Boyapati, A., Miao, Y., Wang, Y., Chen, I.-M., Chen, Z., Rowley, J. D., Willman, C. L., & Zhang, D.-E.
- Affiliations
- Scripps Research Institute (US)
- University of New Mexico (US)
- Soochow University (CN)
- University of Chicago (US)
- Corresponding author
- Zhang, Dong-Er
- Venue
- Nature Medicine
- Published
- 2006-07-30
- Volume
- 12
- Issue
- 8
- Pages
- 945-949
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2038583094
- Cited by
- 279
- References
- 30
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 14 · 2023: 17 · 2022: 6 · 2021: 9 · 2020: 11 · 2019: 16 · 2018: 15 · 2017: 19 · 2016: 16 · 2015: 18 · 2014: 13 · 2013: 18 · 2012: 16
- FWCI
- 9.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (F32HL079900)
- National Cancer Institute (CA 104509, R01CA096735, CA096735, R01CA104509)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- AML1-ETO fusion protein, alternative splicing, RUNX1, RUNX1T1, acute myeloid leukemia, leukemogenesis, myeloid differentiation
- MeSH terms
- RUNX1 Translocation Partner 1 Protein, Amino Acid Sequence, Animals, Cell Line, Chromosomes, Human, Pair 21, Chromosomes, Human, Pair 8, Disease Models, Animal, Exons, Humans, Mice, Inbred C57BL, Mice, Inbred Strains, Mice, Transgenic, Molecular Sequence Data, Neoplasm Transplantation, Retroviridae, Translocation, Genetic, Leukemia, Myeloid, Acute, Oncogene Proteins, Fusion, Alternative Splicing, Protein Structure, Tertiary, Jurkat Cells, Protein Isoforms, Core Binding Factor Alpha 2 Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.